Rockwell Medical, Inc.
RMTIHealthcare|Drug Manufacturers - Specialty & Generic|US
$7.73
+0.13 (+1.71%)
Tangible Book / Share
$6.26
Cash / Share
$6.26
Clinical Trials (20)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04689932 Triferic AVNU Infusion Via Freedom Pump During Hemodialysis | End Stage Renal Disease | P4 | Completed | 12 | Open-label | Triferic AVNU |
| NCT04239391 Hemoglobin Maintenance in Pediatric ESRD (End-stage Renal Disease) Patients by Ferric Pyrophosphate Citrate (FPC) | End Stage Renal Disease | P3 | Unknown | 150 | RCT, Open-label | Triferic |
| NCT01322347 Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2) | Renal Failure Chronic Requiring Hemodialysis | P3 | Completed | 294 | RCT, Single-blind | Soluble Ferric Pyrophosphate (SFP) |
| NCT01503021 Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis | End Stage Renal Disease, Chronic Kidney Disease | P3 | Completed | 718 | RCT, Double-blind | SFP |
| NCT01320202 Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients | Renal Failure Chronic Requiring Hemodialysis | P3 | Completed | 305 | RCT, Single-blind | Soluble Ferric Pyrophosphate (SFP) |
| NCT01894906 Quantitative Mass Transfer of SFP-iron From Dialysate to Blood in CKD-HD Patients | Kidney Failure | P1P2 | Completed | 12 | RCT, Open-label | Soluble Ferric Pyrophosphate |
| NCT04409132 Study to Investigate the Pharmacokinetic Comparability of Dosing Triferic AVNU IV by Continuous Infusion and IV Bolus. | End Stage Renal Disease | P1P2 | Completed | 23 | RCT, Open-label | Triferic |
| NCT02595437 Triferic Pediatric Pharmacokinetic Protocol | End Stage Renal Disease | P1P2 | Completed | 22 | Open-label | Triferic |
| NCT00548249 Dose Ranging Study of Dialysate Containing Soluble Iron to Treat Subjects With End Stage Renal Disease (ESRD) Receiving Chronic Hemodialysis | End-Stage Renal Disease (ESRD) | P2 | Completed | 131 | RCT, Double-blind | Soluble Ferric Pyrophosphate, Soluble Ferric Pyrophosphate, Soluble Ferric Pyrophosphate, Soluble Ferric Pyrophosphate |
| NCT05110768 Treatment of (IDA) by (FPC) Delivered Via Infusion Pump in Patients Receiving Home Infusion Therapy | Iron Deficiency Anemia | P2 | Unknown | 75 | RCT, Open-label | Triferic AVNU |
| NCT04042324 A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients | End Stage Renal Disease | P1P2 | Completed | 12 | RCT, Open-label | Triferic, Heparin |
| NCT02905981 Triferic IRIDA (Iron-Refractory Iron-Deficiency Anemia) Protocol | Iron-Refractory Iron-Deficiency Anemia | P2 | Terminated | 1 | Open-label | Fer-In-Sol, Shohl's solution, Triferic |
| NCT03303144 Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients | End Stage Renal Disease | P1P2 | Completed | 27 | RCT, Open-label | Triferic |
| NCT01286012 Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients | End Stage Renal Disease | P2 | Completed | 108 | RCT, Double-blind | Soluble Ferric Pyrophosphate in liquid bicarbonate, Placebo: Conventional liquid bicarbonate, Erythrocyte Stimulating Agent (ESA), Intravenous (IV) Iron |
| NCT02767128 Pharmacokinetics and Absolute Bioavailability of Fer-In-Sol and Triferic Administered Orally With Shohl's Solution in Healthy Volunteers | Iron-refractory, Iron-deficiency Anemia (IRIDA) | P1 | Completed | 14 | RCT, Open-label | Triferic, Fer-In-Sol, Shohl's solution |
| NCT01920854 A Single Ascending Dose Study of Soluble Ferric Pyrophosphate Administered Intravenously in Healthy Volunteers. | Kidney Failure, Chronic Therapy; Hemodialysis | P1 | Completed | 48 | RCT, Double-blind | soluble ferric pyrophosphate, Placebo |
| NCT02739100 Pharmacokinetics and Preliminary Bioequivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients | End Stage Renal Disease | P1 | Completed | 13 | RCT, Open-label | Triferic |
| NCT02909153 Study of Intraperitoneal Triferic in Patients on Chronic Peritoneal Dialysis | Peritoneal Dialysis (PD), Anemia | P1 | Completed | 30 | RCT, Open-label | Triferic |
| NCT02636049 Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Intravenously to Healthy Adult Volunteers | End Stage Renal Disease | P1 | Completed | 12 | Open-label | Triferic |
| NCT00604565 Delivery of Soluble Ferric Pyrophosphate (SFP) Via the Dialysate to Maintain Iron Balance in Hemodialysis Patients | End Stage Renal Disease (ESRD) | N/A | Terminated | 11 | RCT, Double-blind | soluble ferric pyrophosphate (SFP) |